HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toshio Miyata Selected Research

1- (5- hydroxy- 3- methyl- 1- phenyl- 1H- pyrazol- 4- yl)- 6- methyl- 1,3- dihydrofuro(3,4- c)pyridine- 7- ol

8/2009Methylglyoxal contributes to the development of insulin resistance and salt sensitivity in Sprague-Dawley rats.
2/2008A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models.
12/2007A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toshio Miyata Research Topics

Disease

32Hypoxia (Hypoxemia)
04/2018 - 12/2003
16Diabetic Nephropathies (Diabetic Nephropathy)
01/2016 - 01/2002
15Fibrosis (Cirrhosis)
02/2021 - 10/2001
14Hypertension (High Blood Pressure)
11/2021 - 05/2003
14Obesity
11/2021 - 12/2005
13Inflammation (Inflammations)
04/2020 - 05/2003
11Proteinuria
03/2015 - 10/2001
10Hyperglycemia
01/2016 - 12/2003
8Metabolic Syndrome (Dysmetabolic Syndrome X)
11/2021 - 06/2005
8Thrombosis (Thrombus)
10/2021 - 10/2001
8Chronic Renal Insufficiency
01/2017 - 07/2004
7Cardiovascular Diseases (Cardiovascular Disease)
10/2021 - 02/2008
6Insulin Resistance
11/2021 - 04/2008
6Neoplasms (Cancer)
02/2021 - 04/2008
6Schizophrenia (Dementia Praecox)
01/2021 - 06/2010
6Chronic Kidney Failure (Chronic Renal Failure)
10/2020 - 01/2002
6Body Weight (Weight, Body)
01/2020 - 12/2005
6Ischemia
08/2012 - 12/2005
5Hemorrhage
10/2017 - 05/2010
4Albuminuria
01/2016 - 04/2008
4Renal Insufficiency (Renal Failure)
01/2013 - 10/2003
4Hyperinsulinism (Hyperinsulinemia)
02/2010 - 04/2008
4Uremia
09/2005 - 10/2001
3Psychotic Disorders (Schizoaffective Disorder)
11/2021 - 01/2011
3Type 2 Diabetes Mellitus (MODY)
04/2018 - 04/2008
3Polycythemia (Erythrocytosis)
08/2015 - 02/2010
3Thrombotic Microangiopathies
03/2015 - 10/2001
3Anemia
10/2013 - 10/2001
3Nephritis
05/2013 - 12/2005
3Kidney Diseases (Kidney Disease)
01/2012 - 02/2006
2BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
06/2022 - 01/2021
2Hyperlipidemias (Hyperlipidemia)
11/2021 - 01/2010
2Non-alcoholic Fatty Liver Disease
12/2018 - 10/2017
2Multiple Sclerosis
04/2018 - 01/2015
2Alzheimer Disease (Alzheimer's Disease)
01/2018 - 08/2002
2Cardiomegaly (Heart Hypertrophy)
01/2017 - 11/2013
2Diabetic Retinopathy (Retinopathy, Diabetic)
03/2015 - 12/2012

Drug/Important Bio-Agent (IBA)

28Advanced Glycation End ProductsIBA
04/2018 - 08/2002
23Plasminogen Activator Inhibitor 1IBA
11/2021 - 04/2008
18Plasminogen Activators (Plasminogen Activator)IBA
06/2022 - 05/2010
14Proteins (Proteins, Gene)FDA Link
03/2015 - 01/2002
11Glucose (Dextrose)FDA LinkGeneric
11/2021 - 04/2003
115- chloro- 2- (((2- (4- (diphenylmethyl)piperazin- 1- yl)- 2- oxoethoxy)acetyl)amino)benzoateIBA
10/2020 - 05/2010
9TM5441IBA
01/2021 - 11/2013
9Pharmaceutical PreparationsIBA
01/2021 - 05/2003
8Oxygen (Dioxygen)IBA
08/2015 - 01/2008
8Antihypertensive Agents (Antihypertensives)IBA
04/2010 - 05/2003
7pentosidineIBA
01/2018 - 10/2001
7Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2014 - 10/2001
6EnzymesIBA
11/2021 - 05/2003
5Biomarkers (Surrogate Marker)IBA
11/2021 - 09/2009
5Transcription Factors (Transcription Factor)IBA
04/2018 - 11/2005
5Insulin (Novolin)FDA Link
11/2017 - 05/2003
5ErythropoietinFDA Link
02/2016 - 10/2001
5Messenger RNA (mRNA)IBA
01/2016 - 09/2008
4Vitamin B 6IBA
01/2021 - 06/2010
4CollagenIBA
10/2020 - 01/2012
4Plasminogen InactivatorsIBA
02/2016 - 05/2010
4Prolyl Hydroxylases (Prolyl Hydroxylase)IBA
02/2016 - 12/2009
4LuciferasesIBA
01/2015 - 05/2006
4ElementsIBA
01/2015 - 12/2004
4Receptor for Advanced Glycation End ProductsIBA
03/2014 - 07/2004
4Nitric Oxide Synthase (NO Synthase)IBA
11/2013 - 10/2001
4LipidsIBA
10/2013 - 04/2008
4Pyruvaldehyde (Methylglyoxal)IBA
04/2013 - 04/2003
4olmesartanIBA
10/2009 - 05/2003
3SugarsIBA
11/2021 - 12/2018
3Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
10/2020 - 10/2001
3CytokinesIBA
01/2020 - 01/2012
3PyridoxamineIBA
04/2018 - 01/2016
3Streptozocin (Streptozotocin)FDA Link
01/2016 - 05/2006
3NG-Nitroarginine Methyl Ester (L-NAME)IBA
01/2015 - 10/2001
3AlbuminsIBA
01/2014 - 03/2008
3Lactoylglutathione LyaseIBA
07/2013 - 04/2009
3SaltsIBA
04/2013 - 08/2007
38-Hydroxy-2'-DeoxyguanosineIBA
04/2013 - 01/2002
3Angiotensin IIIBA
08/2012 - 01/2007
3Transforming Growth Factor beta (TGF-beta)IBA
01/2010 - 04/2008
3Angiotensin II Type 1 Receptor BlockersIBA
09/2009 - 05/2003
31- (5- hydroxy- 3- methyl- 1- phenyl- 1H- pyrazol- 4- yl)- 6- methyl- 1,3- dihydrofuro(3,4- c)pyridine- 7- olIBA
08/2009 - 12/2007
3Angiotensin Receptor AntagonistsIBA
12/2008 - 05/2004
3CobaltIBA
11/2008 - 12/2005
3Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA
09/2008 - 01/2002
3TunicamycinIBA
05/2008 - 12/2005
2Sucrose (Saccharose)IBA
11/2021 - 01/2016
2Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
01/2020 - 01/2012
2N(6)-carboxymethyllysine (carboxymethyllysine)IBA
04/2018 - 10/2001
2Amino AcidsFDA Link
04/2018 - 10/2003
2Valsartan (Vals)FDA Link
04/2018 - 09/2009
2Therapeutic UsesIBA
10/2017 - 11/2016
2Apolipoproteins E (ApoE)IBA
05/2017 - 10/2014
2Syntex adjuvant formulationIBA
01/2017 - 03/2015
2FibrinolysinFDA Link
01/2016 - 09/2008
2Protein Isoforms (Isoforms)IBA
08/2015 - 10/2001

Therapy/Procedure

8Therapeutics
10/2020 - 06/2005
4Oral Administration
04/2020 - 12/2007
4Caloric Restriction
11/2008 - 06/2005
2Fat-Restricted Diet (Diet, Fat Restricted)
01/2021 - 01/2010
2Peritoneal Dialysis
10/2020 - 09/2005
2Injections
04/2020 - 06/2004